Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E17.47 EPS (ttm)4.10 Insider Own0.10% Shs Outstand1.60B Perf Week1.56%
Market Cap114.07B Forward P/E11.04 EPS next Y6.48 Insider Trans-30.96% Shs Float1.59B Perf Month-1.38%
Income6.62B PEG1.25 EPS next Q1.38 Inst Own70.60% Short Float1.32% Perf Quarter8.48%
Sales26.71B P/S4.27 EPS this Y16.20% Inst Trans0.99% Short Ratio4.08 Perf Half Y15.47%
Book/sh3.77 P/B18.97 EPS next Y17.49% ROA10.00% Target Price76.89 Perf Year8.09%
Cash/sh4.52 P/C15.83 EPS next 5Y13.93% ROE119.70% 52W Range55.06 - 75.04 Perf YTD14.21%
Dividend2.56 P/FCF41.71 EPS past 5Y10.90% ROI18.00% 52W High-4.69% Beta1.50
Dividend %3.58% Quick Ratio1.30 Sales past 5Y8.00% Gross Margin76.70% 52W Low29.89% ATR1.01
Employees30000 Current Ratio1.40 Sales Q/Q7.60% Oper. Margin36.70% RSI (14)51.73 Volatility1.28% 1.45%
OptionableYes Debt/Eq6.20 EPS Q/Q21.30% Profit Margin24.80% Rel Volume0.59 Prev Close71.75
ShortableYes LT Debt/Eq5.63 EarningsJul 28 BMO Payout58.90% Avg Volume5.15M Price71.52
Recom2.40 SMA200.92% SMA50-0.24% SMA2009.18% Volume3,065,817 Change-0.32%
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Aug-23-17 02:15PM  AbbVie, Inc. : ABBV-US: Dividend Analysis : July 14th, 2017 (record date) : By the numbers : August 23, 2017 Capital Cube
09:07AM  Key Developments for Allergan in 2Q17 Market Realist
09:03AM  AbbVie, Inc. breached its 50 day moving average in a Bullish Manner : ABBV-US : August 23, 2017 Capital Cube
08:04AM  3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences Motley Fool
07:37AM  How Allergans International Segment Performed in 2Q17 Market Realist
Aug-22-17 07:06PM  5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed TheStreet.com
Aug-21-17 02:19PM  Gilead: Where's the Urgency? Barrons.com
01:31PM  Vertex Pharmaceuticals Incorporated (VRTX) Stock Is Too Expensive InvestorPlace
11:46AM  AbbVie, Inc. :ABBV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 21, 2017 Capital Cube
08:21AM  Better Buy: AbbVie Inc. vs. Pfizer Inc. Motley Fool
Aug-20-17 07:22AM  3 Dividend Stocks I'd Buy Right Now Motley Fool
Aug-18-17 10:32AM  AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada Zacks
Aug-17-17 10:05AM  Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst TheStreet.com
09:03AM  AbbVie's MAVIRET Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes CNW Group
07:35AM  3 Value Stocks for Retirees Motley Fool
Aug-16-17 09:32AM  What Does AbbVies Dividend Curve Look Like? Market Realist
08:00AM  3 Dividend Healthcare Stocks Motley Fool
Aug-14-17 05:31PM  AbbVie, Inc. Value Analysis (NYSE:ABBV) : August 14, 2017 Capital Cube
03:42PM  Big-name U.S. hedge funds shed healthcare stocks during the rally in Q2 Reuters
08:02AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
Aug-12-17 11:44AM  3 High-Yield Dividend Stocks I'd Buy Right Now Motley Fool
08:01AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
Aug-11-17 10:18AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : August 11, 2017 Capital Cube
08:02AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
Aug-10-17 06:30PM  3 Value Stocks for Wise Investors Motley Fool
09:07AM  Celgenes Otezla Witnessed High Revenue Growth in 2Q17 Market Realist
08:40AM  Short Sellers Hike Bets in Major Pharma 24/7 Wall St.
Aug-09-17 08:46AM  Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data Zacks
Aug-07-17 11:31AM  3 Value Stocks for Retirement Motley Fool
10:37AM  An Update on AbbVies Clinical Pipeline in 2017 Market Realist
09:54AM  Top 4 Marijuana Stocks to Watch for August 2017 Investopedia
09:08AM  Upadacitinib: Opportunity for AbbVies Long-Term Growth? Market Realist
08:00AM  AbbVie Wages HCV Drug-Price War on Gilead Bloomberg
07:38AM  Imbruvica Could Significantly Drive AbbVies Revenue Growth Market Realist
Aug-06-17 12:21PM  AbbVie's Mavyret Approved for Commercialization in US GuruFocus.com
11:02AM  The Top Stock You Should Consider for Your IRA Motley Fool
10:37AM  AbbVies new, cheaper hepatitis C drug could launch the drug worlds own Hunger Games MarketWatch
Aug-05-17 06:45AM  Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance? Motley Fool
Aug-04-17 11:46PM  [$$] Another Price Squeeze for Drug Makers The Wall Street Journal
04:29PM  Infinity (INFI) Q2 Loss Wider than Expected, View Intact Zacks
02:25PM  [$$] Another Price Squeeze for Drug Makers The Wall Street Journal
02:05PM  AbbVies Humira Continues to Generate High Revenues Market Realist
01:32PM  How AbbVie's 'Gauntlet' Could Squeeze Gilead's Drugs In Hepatitis C Investor's Business Daily
01:00PM  NBIX: Strong Start to INGREZZA® Launch Zacks Small Cap Research
12:36PM  How Did AbbVie Perform in 2Q17? Market Realist
10:39AM  Analysts Recommendations for AbbVie in August 2017 Market Realist
Aug-03-17 06:27PM  The FDA Just Approved the First Drug That Can Treat All Hepatitis C Strains in Just 8 Weeks Fortune
05:53PM  FDA OKs new drug to treat all forms of hepatitis C Associated Press
05:53PM  FDA OKs new drug to treat all forms of hepatitis C Associated Press
05:04PM  Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat Zacks
04:01PM  FDA approves AbbVie's hepatitis C drug Reuters
03:28PM  AbbVie Receives U.S. FDA Approval of MAVYRET (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks PR Newswire
01:44PM  Why OraSure Technologies, Inc. Jumped Higher Today Motley Fool
Aug-02-17 01:07PM  U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) -- A Serious, Potentially Life-Threatening Condition -- After Failure of One or More Lines of Systemic Therapy PR Newswire
Aug-01-17 10:30AM  3 Growth Stocks for the Long Term Motley Fool
09:13AM  How Gilead Sciences Performed in 2Q17 Market Realist
07:43AM  Analysts Recommendations for Gilead Sciences in July 2017 Market Realist
07:30AM  Featured Company News EC Grants AbbVie's MAVIRET Marketing Authorization for Treatment of Chronic Hepatitis C ACCESSWIRE
07:29AM  Key FDA Events to Watch Out for in Aug 2017 Zacks
Jul-31-17 04:26PM  5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You Motley Fool
11:10AM  Edited Transcript of ABBV earnings conference call or presentation 28-Jul-17 1:00pm GMT Thomson Reuters StreetEvents
10:30AM  Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY Zacks
10:05AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : July 31, 2017 Capital Cube
09:56AM  J&J arthritis drug sirukumab raises safety concerns -FDA staff Reuters
08:37AM  J&J arthritis drug sirukumab raises safety concerns - FDA staff Reuters
Jul-28-17 10:55PM  AbbVie tops Street 2Q forecasts Associated Press
04:30PM  AbbVie Topples As Humira Sales Brake For Third Straight Quarter Investor's Business Daily
04:28PM  AbbVie's drug for all types of hepatitis C wins EU approval Reuters
03:20PM  AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact Zacks
12:32PM  AbbVie to remain cautious on drug pricing, shares fall Reuters
10:57AM  European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) PR Newswire
09:48AM  AbbVie Inc (ABBV) Q2 Beat Fueled by Best Worlds Best-Selling Drug InvestorPlace
08:54AM  4 Drug Stocks in Focus this World Hepatitis Day Zacks
08:40AM  Stock Futures Lower on Amazon's Earnings Disappointment, U.S. Economy Grows 2.6% in Q2 TheStreet.com
08:20AM  Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens TheStreet.com
08:13AM  AbbVie (ABBV) Tops Q2 Earnings and Revenue Zacks
08:12AM  AbbVie's profit beats on robust Humira demand Reuters
07:56AM  AbbVie shares surge 2% on Q2 profit, revenue beats MarketWatch
07:42AM  AbbVie Reports Second-Quarter 2017 Financial Results PR Newswire
07:00AM  Gilead's HCV and HIV Drugs Support Wide Moat Morningstar
Jul-27-17 04:34PM  Friday's Earnings Reports To Watch: XOM, CVX, MRK, ABBV Zacks
04:29PM  Q2 GDP, Big Oil, Merck, AbbVie, American Air: Investing Action Plan Investor's Business Daily
10:42AM  Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK Zacks
10:07AM  Gilead Sciences: The Biggest of Beats? Barrons.com
Jul-26-17 07:30PM  Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense Motley Fool
06:13PM  Gilead Sciences profit falls, but beats Wall Street estimates Reuters
Jul-25-17 08:00AM  AbbVie Several Candidates to Replace Humira in the Pipeline Accesswire
12:57AM  [$$] AbbVie Ordered to Pay $150 Million in AndroGel Lawsuit The Wall Street Journal
Jul-24-17 07:00PM  [$$] AbbVie Ordered to Pay $150 Million in AndroGel Lawsuit The Wall Street Journal
04:43PM  U.S. jury finds AbbVie liable for misrepresentation in AndroGel verdict Reuters
04:42PM  Why Reata Pharmaceuticals Is Rallying 17.5% Today Motley Fool
02:42PM  U.S. jury finds AbbVie liable for misrepresentation in first AndroGel verdict Reuters
01:56PM  AbbVie Ordered to Pay $150 Million Damages in Low-T Trial Bloomberg
10:11AM  Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs Zacks
08:22AM  Better Buy: Johnson & Johnson vs. AbbVie Motley Fool
Jul-23-17 11:50AM  3 Stocks That Are Absurdly Cheap Right Now Motley Fool
07:27AM  These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet Motley Fool
Jul-22-17 10:30AM  Better Buy: AbbVie Inc. vs. Johnson & Johnson Motley Fool
Jul-21-17 04:22PM  AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store? Zacks
09:36AM  AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis PR Newswire
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; and Principia Biopharma Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Option Exercise51.42193,1319,930,796469,623Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Sale71.00193,13113,713,186276,492Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Option Exercise51.4222,0381,133,194364,391Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Sale71.0722,0381,566,166276,492Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Option Exercise51.4265,8613,386,573342,353Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Sale71.0065,8614,676,131298,530Aug 04 05:01 PM
RAPP EDWARD JDirectorJul 31Buy70.454,000281,78215,498Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.0918,0001,261,63883,737Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.4230021,12783,437Aug 02 05:06 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Option Exercise24.2145,8001,108,736160,545Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Option Exercise29.2379,8002,332,275187,625Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Sale70.0079,8005,586,000107,825Jun 15 05:05 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Sale70.0045,8003,206,000114,745Jun 15 05:05 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 19Sale65.4971,2354,665,063278,727May 23 05:13 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Option Exercise28.6238,3001,095,994221,843May 19 05:01 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Sale65.3538,3002,502,905183,543May 19 05:01 PM
ALBAN CARLOSEVP, Commercial OperationsMay 04Sale67.0043,0002,881,000114,745May 08 05:13 PM
AbbVie Inc.10% OwnerMar 28Sale22.50450,00010,125,0001,190,473Mar 30 05:48 PM
Schumacher Laura JExecutive Vice PresidentMar 10Sale65.2640,0002,610,257107,825Mar 10 05:22 PM
Michael Robert A.VP, ControllerMar 10Sale65.295,132335,06816,706Mar 10 05:22 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 10Sale65.2922,4511,465,82626,078Mar 10 05:21 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Option Exercise27.9572,0162,012,610422,763Mar 10 05:20 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Sale64.2572,0164,627,028350,747Mar 10 05:20 PM
HURWICH THOMAS A.VP, ControllerFeb 28Sale61.892,311143,03167,276Mar 02 06:12 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 02Option Exercise27.292,40065,4965,431Feb 03 05:21 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Option Exercise27.296,600180,114178,970Dec 02 05:08 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Sale59.196,600390,654172,370Dec 02 05:08 PM
HURWICH THOMAS A.VP, ControllerNov 16Option Exercise28.863,10089,47564,549Nov 18 05:39 PM
HURWICH THOMAS A.VP, ControllerNov 16Sale62.003,100192,20061,449Nov 18 05:39 PM
Schumacher Laura JExecutive Vice PresidentSep 07Sale65.0050,0003,250,000144,138Sep 09 05:38 PM